A large-scale lentivirus manufacturing platform to accelerate time to clinic: video & poster

Watch the video to learn more about:

LentiSure™, a proven large-scale lentivirus production platform to accelerate time to clinic of lentivirus-based cell and gene therapies
Achieving high titers, transduction efficiency, dependability, and scalable production processes with improved purification methods
Optimized analytical methods to allow faster development and improved patient results

Fill out the form to watch LentiSure vidéo (10min)

Name*
First Last
Job title*
Company/Institution*
City*
Country*
State*
Email*
GDPR confirmation*
- By submitting this form you agree that the information collected on this form may be stored in a computer file by the company's marketing department and processed by the department concerned in order to best respond to your request. They are kept unless you expressly agree otherwise. In accordance with the amended "informatique et libertés" law, you can exercise your right of access to your personal data and have them rectified or deleted by contacting: contact@yposkesi.com.
Newsletter subscription
- I would like to receive more information about Yposkesi’s viral vector cGMP manufacturing services. I confirm that I have reviewed and agree with Yposkesi's privacy policy.
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

Do you prefer to read a poster?

Download Fast Fact LentiSure poster

Name*
First Last
Job title*
Company/Institution*
City*
Country*
State*
Email*
GDPR confirmation*
- By submitting this form you agree that the information collected on this form may be stored in a computer file by the company's marketing department and processed by the department concerned in order to best respond to your request. They are kept unless you expressly agree otherwise. In accordance with the amended "informatique et libertés" law, you can exercise your right of access to your personal data and have them rectified or deleted by contacting: contact@yposkesi.com.
Newsletter subscription
- I would like to receive more information about Yposkesi’s viral vector cGMP manufacturing services. I confirm that I have reviewed and agree with Yposkesi's privacy policy.
CAPTCHA
Email
This field is for validation purposes and should be left unchanged.

About the speaker: Brian Mullan, PhD, Chief Technical Officer at Yposkesi

Brian joined Yposkesi as Chief Technical Officer in 2020. With over 20 years of experience working internationally (Europe, USA) with large multinational companies, Brian has held leadership roles in late-phase process development, product launch, and commercial supply for large pharmaceutical companies making therapeutic monoclonal antibodies (MAbs). He spent nine years at Novartis, where he held posts as head of manufacturing science and technology and as a global technical project leader. Between 2008 and 2012, he was process tech transfer lead at Eli Lilly. Prior to that, he worked at Janssen (Centocor) Biologics and Sanofi-Aventis (in the area of C&GT R&D). He holds a PhD in Viral Genetics from University College Cork, Ireland, and an MBA from the Open University Business School, UK.

< Previous article Yposkesi’s new biomanufacturing site: interview with our Chief Operational Officer

Next article > Analytical Quality by Design approach: a challenge for Viral Vector Testing in Gene Therapy